Three new investors, including Bold Capital and Bold Longevity Growth Fund, joined previous investors Genoa Ventures, Manta Ray Ventures, and Yu Galaxy in participating in the oversubscribed round. Additional capital was also provided by a strategic investor in the diagnostics space, further strengthening Aqtual's ability to advance the platform and its applications as it moves towards the commercialization of Aqtual's first flagship product: a therapy response prediction test in rheumatoid arthritis (RA).

Aqtual is a precision medicine company developing products for chronic disease management and oncology utilizing a novel cell-free DNA-based platform. Aqtual's proprietary platform evaluates protein regulation, epigenetics, and transcriptomics solely using cell-free DNA fragments found in the blood. The platform yields efficient and robust real-time analysis of disease and treatment while overcoming the limitations of previous cell-free DNA methodologies.